| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Cash Flows Used In Operating Activities | ||||||
Net loss | ||||||
-305,580 | -54,191 | -69,767 | -226,778 | 319,814 | -25,246 | 20,023 |
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | ||||||
Gain on consolidation | ||||||
- | - | - | - | 414,133 | 0 | 0 |
Change in fair value of contingent consideration and indemnification asset | ||||||
-3,997 | -4,104 | 400 | -2,086 | 0 | 0 | - |
Gain on disposal of assets | ||||||
9,600 | 0 | 0 | - | - | - | - |
Loss from lease abandonment | ||||||
- | - | - | -6,456 | 0 | 0 | - |
Gain on deconsolidation | ||||||
- | - | - | - | - | - | 46,246 |
Loss from equity method investees | ||||||
-9,465 | -4,736 | -1,755 | -841 | -28,165 | -25,246 | -4,241 |
Depreciation and amortization expenses | ||||||
60,913 | 44,515 | 32,368 | 17,224 | 7,166 | 0 | 1,208 |
Goodwill impairment | ||||||
199,800 | 0 | 0 | 160,600 | 0 | 0 | - |
Stock-based compensation expense | ||||||
15,618 | 17,609 | 20,437 | 18,604 | 14,730 | 0 | 91 |
Acceleration of unvested equity awards for Valence Health employees | ||||||
- | - | - | 3,897 | 0 | 0 | - |
Deferred tax provision (benefit) | ||||||
-23,124 | 44 | -7,271 | -10,755 | 23,460 | 0 | 0 |
Amortization of contract cost assets | ||||||
5,723 | 2,703 | 0 | 0 | - | - | - |
Amortization of deferred financing costs | ||||||
9,370 | 2,455 | 914 | 0 | 0 | - | - |
Interest from customer advance for regulatory capital requirements | ||||||
1,300 | 0 | 0 | - | - | - | - |
Other current operating cash inflows (outflows), net | ||||||
264 | -448 | -490 | -916 | -172 | 0 | -827 |
Changes in assets and liabilities, net of acquisitions: | ||||||
Accounts receivable, net and contract assets | ||||||
-6,326 | 24,503 | 11,258 | 11,044 | -11,756 | 0 | 8,670 |
Prepaid expenses and other current and noncurrent assets | ||||||
-791 | 14,746 | -2,729 | 9,968 | 2,036 | 0 | 2,162 |
Contract cost assets | ||||||
23,057 | 11,179 | 0 | 0 | - | - | - |
Accounts payable | ||||||
-5,480 | 7,598 | 5,563 | -6,371 | 2,764 | 0 | -843 |
Accrued liabilities | ||||||
-21,852 | 12,180 | -2,781 | 15,229 | -3,788 | 0 | 1,193 |
Accrued compensation and employee benefits | ||||||
9,246 | -14,571 | -3,303 | 6,678 | 11,402 | 0 | 4,144 |
Deferred revenue | ||||||
-756 | -1,819 | 3,548 | 1,200 | -17,998 | 0 | 8,677 |
Reserve for claims and performance-based arrangements | ||||||
33,555 | 8,964 | 0 | - | - | - | - |
Right-of-use operating assets | ||||||
20,811 | 0 | 0 | - | - | - | - |
Operating lease liabilities | ||||||
27,724 | 0 | 0 | - | - | - | - |
Claims reserves | ||||||
- | - | - | 0 | - | - | - |
Other current liabilities | ||||||
- | - | - | - | - | 0 | 3,888 |
Other long-term liabilities | ||||||
-5,355 | 3,210 | -1,782 | -153 | 58 | 0 | - |
Net cash and restricted cash used in operating activities | ||||||
-42,645 | -20,651 | -27,958 | -35,510 | -18,468 | 0 | -13,629 |
Cash Flows Used In Investing Activities | ||||||
Cash paid for asset acquisitions or business combinations | ||||||
8,575 | 130,241 | 3,694 | 82,560 | 0 | 0 | - |
Customer advance for regulatory capital requirements | ||||||
46,400 | 0 | 0 | - | - | - | - |
Loan for implementation funding | ||||||
0 | 0 | 20,000 | 0 | 0 | - | - |
Principal repayment of implementation funding loan and regulatory and capital requirements | ||||||
5,400 | 20,000 | 0 | 0 | - | - | - |
Amount received from escrow in asset acquisition | ||||||
0 | 500 | 0 | 0 | 13,065 | 0 | 0 |
Cash transferred upon deconsolidation of affiliate | ||||||
- | - | - | - | - | - | 15,521 |
Investments in and advances to equity method investees | ||||||
87,480 | 9,360 | 1,128 | 3,000 | 0 | 0 | - |
Purchases of investments | ||||||
11,125 | 10,010 | 0 | 0 | 54,234 | 0 | 0 |
Maturities and sales of investments | ||||||
2,575 | 349 | 44,210 | 9,379 | 4,000 | 0 | 0 |
Investments in and purchases of property and equipment | ||||||
35,534 | 39,550 | 27,848 | 15,526 | 6,515 | 0 | 10,438 |
Purchases of restricted investments | ||||||
- | - | - | - | 0 | - | - |
Purchase and maturities of restricted investments | ||||||
495 | -7,937 | 3,805 | 4,950 | - | 0 | - |
Change in restricted cash | ||||||
- | - | - | - | - | - | 50 |
Net cash and restricted cash used in investing activities | ||||||
-181,634 | -160,375 | -12,265 | -96,657 | -43,684 | 0 | -25,909 |
Cash Flows (Used In) from Financing Activities | ||||||
Proceeds from issuance of common stock, net of stock issuance costs | ||||||
0 | 0 | 166,947 | 0 | 209,087 | 0 | 0 |
Changes in working capital balances related to claims processing on behalf of partners | ||||||
-104,268 | 96,153 | -4,200 | 28,041 | 6,285 | - | - |
Amount received from escrow in asset acquisition | ||||||
500 | 0 | 0 | - | - | - | - |
Proceeds from stock option exercises | ||||||
1,092 | 11,929 | 4,082 | 1,259 | 152 | 0 | 0 |
Change in warrant liability | ||||||
7,092 | 0 | 0 | - | - | - | - |
Proceeds from issuance of long-term debt, net of issuance costs | ||||||
62,648 | 167,178 | 0 | 121,250 | 0 | 0 | 23,000 |
Payments of deferred offering costs | ||||||
- | - | - | - | 1,361 | 0 | 0 |
Taxes withheld and paid for vesting of restricted stock units | ||||||
2,609 | 1,236 | 1,272 | 365 | 0 | 0 | - |
Net cash and restricted cash (used in) from financing activities | ||||||
-35,545 | 274,024 | 165,557 | 150,185 | 214,163 | 0 | 34,286 |
Effect of exchange rate on cash and cash equivalents and restricted cash | ||||||
30 | -36 | 0 | 0 | - | - | - |
Net increase (decrease) in cash and cash equivalents | ||||||
-259,794 | 92,962 | 125,334 | 18,018 | 152,011 | 0 | -5,252 |
Supplemental Disclosure of Non-cash Investing and Financing Activities | ||||||
Non-cash contribution of common stock to Evolent Health LLC prior to the Offering Reorganization | ||||||
- | - | - | - | - | 11,091 | 1,235 |
Non-cash deferred financing costs payable | ||||||
- | - | - | - | - | 0 | - |
Acquisition consideration payable | ||||||
- | - | - | - | - | 0 | - |
Accrued property and equipment purchases | ||||||
- | - | - | - | - | 0 | - |
Assumption of non-controlling interest as a result of merger with TPG affiliate | ||||||
- | - | - | - | - | 0 | 0 |
Decrease in non-controlling interests as a result of the Exchange | ||||||
- | - | - | - | - | 0 | 0 |
Non-cash settlement of accounts receivable through reacquisition of Series A preferred stock | ||||||
- | - | - | - | - | - | 219 |
Conversion of accrued interest from convertible notes to equity | ||||||
- | - | - | - | - | - | 469 |
Conversion of convertible notes to equity | ||||||
- | - | - | - | - | - | 12,978 |
Reclassification of deferred offering costs acquired to additional paid-in capital | ||||||
- | - | - | - | - | 0 | 0 |
Decrease in non-controlling interests as a result of Class B Exchanges | ||||||
- | - | - | - | - | 0 | 0 |